Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities

9 Months Ended

Sep. 30, 2016

12. Accrued Expenses and Other Long-Term Liabilities

Accrued expenses and other long-term liabilities, excluding National, consisted of the following:

	September 30,		December 31,
($ in thousands)	2016		2015
Accrued expenses:
Professional fees	$	1,389	$	382
Salaries, bonuses and related benefits		1,777		2,492
Ovamed manufacturing rights - short term component		750		1,500
Research and development		788		810
Dr. Falk Pharma milestone		2,802		2,717
Accrued royalty and coupons		301		-
Lease impairment		95		146
Other		703		523
Total accrued expenses	$	8,605	$	8,570

Other long-term liabilities:
Deferred rent and long-term lease abandonment charge		4,583		584
Total other long-term liabilities	$	4,583	$	584

National's preliminary allocation of fair value of accounts payable and other accrued expenses as of September 9, 2016, consisted of the following:

	September 9,
($ in thousands)	2016
Legal	$	961
Audit		196
Telecommunications		181
Data Services		229
Regulatory		365
Settlements		701
Deferred rent		39
Contingent consideration payable		423
Other		2,984
Total	$	6,079